Compare SiTime Corporation (SITM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Tango Therapeutics Inc. — how do they compare? SiTime Corporation trades at $506 (market cap $17.43B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: SiTime Corporation is far larger — about 4.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and Tango Therapeutics Inc. for 0 Days on average.
| SITM | TNGX | |
|---|---|---|
Market Cap | $17.43B | $3.75B |
Volume | 549,677 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $901.60 | $32.90 |
52-Week Low | $252.76 | $7.50 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $16.84B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $579.66, up 1.68% today, showing strong momentum after recent earnings beats. The stock faces technical headwinds with bearish moving averages but benefits from unanimous analyst buy ratings and a $751.43 consensus price target. Recent Q2 2026 results showed 126.5% revenue growth to $157.43M and the company's first GAAP profit, driven by AI infrastructure demand and the Renesas acquisition.
The outlook remains positive with accelerating AI-driven growth, though high valuations (P/E 966.1) and negative 2025 net income ($-42.9M) pose risks. Institutional buying and strong Q3 guidance support upside potential, but investors should monitor execution on margin expansion and competitive pressures in the timing solutions market.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
